Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CXRXF ADVANZ PHARMA	$17.06	$17.06	$2.13 ▼ $18.00	$834.46M	N/A	11,851 shs	39 shs
LCTX Lineage Cell Therapeutics	$0.99 -3.4%	$0.91	$0.37 ▼ $1.21	$232.92M	1.66	1.55 million shs	2.00 million shs
NRIX Nurix Therapeutics	$11.04 -2.0%	$11.82	$8.18 ▼ $29.56	$860.82M	2.14	999,154 shs	533,693 shs
QURE uniQure	$13.69 -1.7%	$14.83	$4.45 ▼ $19.18	$763.75M	0.11	1.32 million shs	1.06 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CXRXF ADVANZ PHARMA	0.00%	0.00%	0.00%	0.00%	0.00%
LCTX Lineage Cell Therapeutics	-3.40%	-12.81%	-3.40%	+100.79%	-3.40%
NRIX Nurix Therapeutics	-1.95%	-4.17%	-11.25%	-2.04%	-49.54%
QURE uniQure	-1.65%	-9.40%	-4.13%	-7.31%	+78.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	1.76 of 5 stars	3.5	0.0	0.0	0.0	0.6	3.3	0.6
NRIX Nurix Therapeutics	2.5151 of 5 stars	4.4	1.0	0.0	0.0	3.2	0.8	0.0
QURE uniQure	2.4186 of 5 stars	3.5	2.0	0.0	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CXRXF ADVANZ PHARMA	0.00	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	326.27% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	161.47% Upside
QURE uniQure	2.91	Moderate Buy	$36.55	166.95% Upside

Current Analyst Ratings Breakdown

Latest LCTX, NRIX, CXRXF, and QURE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
6/23/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/23/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CXRXF ADVANZ PHARMA	$525.58M	1.59	N/A	N/A	$0.16 per share	106.63
LCTX Lineage Cell Therapeutics	$9.50M	23.68	N/A	N/A	$0.35 per share	2.82
NRIX Nurix Therapeutics	$54.55M	15.47	N/A	N/A	$5.85 per share	1.89
QURE uniQure	$27.12M	27.70	N/A	N/A	($0.07) per share	-195.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CXRXF ADVANZ PHARMA	-$74.86M	N/A	N/A	∞	N/A	-15.31%	N/A	-4.38%	N/A
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-169.57%	-22.64%	-15.27%	8/6/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	N/A

Latest LCTX, NRIX, CXRXF, and QURE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LCTX Lineage Cell Therapeutics	-$0.02	N/A	N/A	N/A	$1.47 million	N/A
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CXRXF ADVANZ PHARMA	257.04	2.39	1.61
LCTX Lineage Cell Therapeutics	N/A	3.82	3.82
NRIX Nurix Therapeutics	N/A	6.82	6.82
QURE uniQure	1.53	9.98	11.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CXRXF ADVANZ PHARMA	N/A
LCTX Lineage Cell Therapeutics	62.47%
NRIX Nurix Therapeutics	N/A
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
CXRXF ADVANZ PHARMA	N/A
LCTX Lineage Cell Therapeutics	26.80%
NRIX Nurix Therapeutics	7.40%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CXRXF ADVANZ PHARMA	429	48.91 million	N/A	Not Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable

LCTX, NRIX, CXRXF, and QURE Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for uniQure Q3 Earnings?

August 2 at 2:25 AM | americanbankingnews.com

FY2027 Earnings Forecast for uniQure Issued By HC Wainwright

August 1 at 3:17 AM | americanbankingnews.com

Leerink Partnrs Has Bullish Outlook for uniQure Q4 Earnings

August 1 at 2:33 AM | americanbankingnews.com

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

July 31 at 10:56 AM | zacks.com

Brokerages Set uniQure N.V. (NASDAQ:QURE) Price Target at $37.82

July 31 at 2:13 AM | americanbankingnews.com

uniQure (NASDAQ:QURE) Given New $35.00 Price Target at Chardan Capital

July 30 at 3:47 AM | americanbankingnews.com

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

uniQure Narrows Loss in Fiscal Q2

July 29, 2025 | fool.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

July 29, 2025 | zacks.com

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025 | globenewswire.com

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, NRIX, CXRXF, and QURE Company Descriptions

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)

As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.99 -0.03 (-3.40%)

Closing price 08/1/2025 04:10 PM Eastern

Extended Trading

$1.00 +0.02 (+1.80%)

As of 08/1/2025 07:29 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Nurix Therapeutics NASDAQ:NRIX

$11.04 -0.22 (-1.95%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$11.04 0.00 (0.00%)

As of 08/1/2025 05:16 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

uniQure NASDAQ:QURE

$13.69 -0.23 (-1.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$14.21 +0.52 (+3.80%)

As of 08/1/2025 06:46 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time